A vision for building sustainable, self-driven healthcare spanning primary care, secondary care and the wider health and social care system has been set out by medical innovators writing in the Journal of the Royal Society of Medicine.
After finding success investing in the more obviously lucrative corners of American medicine like surgery centers and dermatology practices private equity firms have moved aggressively into the industry's more hidden niches: They are pouring billions into the business of clinical drug trials.
The first few months and years of life are crucial to the development of the human immune system. This is an important phase as the immune system can define which diseases individuals might develop later in life.
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, and the University of Copenhagen announced today the release of the first batch of results from the collaborative work directed to perform multi-omics-based analyses in the context of age-related diseases using an AI-driven target and drug discovery pipeline.
Researchers investigated passive immunization of the fetus and neonates by evaluating the antibody responses elicited by primary and booster doses of maternal SARS-CoV-2 vaccination.